PolitiKit

Advocacy to ensure that proposals to develop or amend federal legislation, regulations, policies or programs that directly or indirectly impact the post-secondary system reflect the needs of universities and support our research and education mission.

Discussions with Innovation, Science and Economic Development Canada and other relevant departments and agencies regarding the role of universities in supporting federal innovation initiatives, policies and programs.

Advocate for support for college-led research as a core component of federal research and innovation funding and policy.

Discussions related to maintaining current funding levels for the College and Community Innovation Program administered by NSERC.

Seeking the participation of content matter experts from the Technology Access Centres in all relevant federal policy discussions concerning applied research and development, and business innovation.

Discussions related to the Interactive Visits program administered by Tech-Access Canada.

Discussions concerning federal budget priorities including support for increasing capacity of Canada's Technology Access Centres, as proposed by Tech-Access Canada.

Advocacy and information sharing on opportunities for fostering a collaborative and impactful innovation ecosystem that supports researchers, the institutions they represent, and commercialization of ideas and property.

Information sharing related to Canada’s defence policy and the opportunities for leveraging existing resourcing at UM.

Discussions with Innovation, Science and Economic Development Canada and other relevant departments and agencies regarding the role of universities in supporting federal innovation initiatives, policies and programs.

Advocacy to ensure that proposals to develop or amend federal legislation, regulations, policies or programs that directly or indirectly impact the post-secondary system reflect the needs of universities and support our research and education mission.

Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities

Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities

Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.

We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).

Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers

Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities

Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities

Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.

Canada Health Act and regulations, as it relates to long-term and home care

Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.

Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.

Incentives and programs to attract and support manufacturing activities in Canada

Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.

Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)

Free trade agreements as they relate to the biopharmaceutical industry

Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).

US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.

Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.

Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.

Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.

Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.

Free Trade agreements as they relate to the biopharmaceutical industry

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

Communication regarding free trade agreements as they relate to the biopharmaceutical industry.

Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.

Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.

The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.

Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.

Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

Continue and increase funding to the Indirect Costs of Research Program in order to maintain an internationally competitive research and development infrastructure

U.S. policies regarding trade as it relates to Canadian automotive, steel, aluminum and critical mineral exports.

U.S. policies regarding tariffs as it relates to Canadian automotive, steel, aluminum and critical mineral exports.

Ensure an automotive strategy provides for a competitive environment that encourages maintenance of current and new automotive investment.

U.S. policies regarding the auto sector as it relates to Canadian automotive, steel, aluminum and critical mineral exports and imports.

USMCA: Participation in consultation group in the renegotiation of the United States, Mexico, Canada agreement, administered by Global Affairs Canada.